A watchdog group is drawing attention to a chemical used in the manufacturing of popular sports bras that can lead to certain types of heart disease. While the chemicals in food and many popular personal Read more…
Posted by Allison Chang (Product Manager, Google Play), Weifang Sun (Product Manager, Chrome OS), Manuel Wang (Product Manager, Google Play Console), and Marcus Leal (Product Manager, Google Play) Your Play Store listing is the best way Read more…
A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura. Poor old Incyte Corporation (INCY) – Get Incyte Corporation Report never seems to catch a break. The drug developer has Read more…
The S&P 500 hit new lows on Oct. 13 after a hot inflation report. Is a bottom nearby? The S&P 500 can often buck the bad news, especially when it’s just one or two negative Read more…
Kristen Radtke / The Verge Soon, Apple Card users will be able to open a “new high-yield Savings account,” Apple says. There’s just one hitch: Apple won’t say what interest rate it’s offering. There’s also Read more…
The Royal Caribbean cruise line has gone back to a policy it used during the early part of its pandemic-era return to sailing. Few, if any cruise passengers miss wearing masks and dealing with ever-changing Read more…
Enlarge / Microsoft 365 will encompass Teams, OneDrive, and the suite of productivity apps formerly known as Office. (credit: Microsoft) Microsoft Office was first released in 1990, and aside from Windows, it’s probably the Microsoft Read more…
A tie-up between Albertsons and Kroger would create a grocery chain giant with combined annual sales of more than $200 billion. Albertsons Companies (ACI) – Get Albertsons Companies Inc. Class A Report shares surged higher Thursday Read more…
Moderna stock is sharply off its highs, but the charts are showing constructive action and investors wonder whether the stock has bottomed. Moderna (MRNA) – Get Moderna Inc. Report shares have been bold in the headlines Read more…
Ginkgo’s recent focus on drug development programs will avoid certain manufacturing risks. It also may hurt the stock’s valuation. Big things begin small. For synthetic-biology specialist Ginkgo Bioworks (DNA) , staying small appears to be Read more…